Cargando…
Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy
SIMPLE SUMMARY: Despite great advances in cancer therapy, tumor heterogeneity continues to be a great barrier for the successful treatment of cancer. It has long been established that tumor heterogeneity is prevelant in most cancer patients and is a major driver of acquired resistance to all forms o...
Autores principales: | El-Sayes, Nader, Vito, Alyssa, Mossman, Karen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918981/ https://www.ncbi.nlm.nih.gov/pubmed/33671881 http://dx.doi.org/10.3390/cancers13040806 |
Ejemplares similares
-
Hypoxia-Driven Immune Escape in the Tumor Microenvironment
por: Vito, Alyssa, et al.
Publicado: (2020) -
Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer
por: Vito, Alyssa, et al.
Publicado: (2021) -
Response to FEC Chemotherapy and Oncolytic HSV-1 Is Associated with Macrophage Polarization and Increased Expression of S100A8/A9 in Triple Negative Breast Cancer
por: Vito, Alyssa, et al.
Publicado: (2021) -
Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells
por: Farrukh, Hadia, et al.
Publicado: (2021) -
A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner
por: El-Sayes, Nader, et al.
Publicado: (2022)